Atomoxetine as a Viable ADHD Treatment in Breastfeeding Mothers: Evidence From Human Milk Pharmacokinetic Analysis

CONCLUSIONS: The transfer of atomoxetine into human milk is minimal, with a 0.19% RID, well below the 5% safety threshold for psychoactive medications. The minimal transfer suggests that maternal atomoxetine use poses a very low risk to breastfed infants, making it a suitable choice for medication management of ADHD in lactating women.

via https://pubmed.ncbi.nlm.nih.gov/41427840/?utm_source=Other&utm_medium=rss&utm_campaign=None&utm_content=1L37KAMf2b_g4WEK3LmdFuKZu9pO3cN7u4ZmO9PPCPeBLMIw1q&fc=None&ff=20260107010905&v=2.18.0.post22+67771e2